ResMed price target raised to A$41 from A$38 at Citi

Citi analyst Mathieu Chevrier raised the firm’s price target on ResMed (RMD) to A$41 from A$38 and keeps a Neutral rating on the shares following the Q2 report. The company reported a “solid” print on strong devices growth but the stock’s valuation is “already there,” the analyst tells investors in a research note.